Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

Published:2014-08 Issue:9 Volume:15 Page:966-974
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

van Rhee Frits,Wong Raymond S,Munshi Nikhil,Rossi Jean-Francois,Ke Xiao-Yan,Fosså Alexander,Simpson David,Capra Marcelo,Liu Ting,Hsieh Ruey Kuen,Goh Yeow Tee,Zhu Jun,Cho Seok-Goo,Ren Hanyun,Cavet James,Bandekar Rajesh,Rothman Margaret,Puchalski Thomas A,Reddy Manjula,van de Velde Helgi,Vermeulen Jessica,Casper Corey

Publisher

Elsevier BV

Subject

Oncology

Reference24 articles.

1. Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C Cabot;Castleman;N Engl J Med,1954

2. Localized mediastinal lymph-node hyperplasia resembling thymoma;Castleman;Cancer,1956

3. Multicentric giant lymph node hyperplasia;Gaba;Am J Clin Pathol,1978

4. Surgery in Castleman's disease: a systematic review of 404 published cases;Talat;Ann Surg,2012

5. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care;Casper;Br J Haematol,2005

Cited by 355 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnostic challenges in patients with Castleman disease, a single center experience from Hungary;Pathology and Oncology Research;2024-08-26

2. Castleman’s disease in the rheumatological practice;Zeitschrift für Rheumatologie;2024-08-22

3. scRNA‐seq reveals the landscape of immune repertoire of PBMNCs in iMCD;Oncogene;2024-08-15

4. Senescence in the bone marrow microenvironment: A driver in development of therapy-related myeloid neoplasms;Journal of Bone Oncology;2024-08

5. Internal Psychometric Validation of an International Burden of Illness Survey for Idiopathic Multicentric Castleman Disease;Oncology and Therapy;2024-07-16